Safety of rolapitant, a novel NK-1 receptor antagonist, for the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients receiving moderately or highly emetogenic chemotherapy (MEC or HEC)

被引：2
|
作者：
Urban, Laszlo
Poma, Allen
Dardeno, Michelle Motta
Martell, Robert E.
机构：
[1] Matrahaza Healthcare Ctr, Matrahaza, Hungary
[2] Univ Teaching Hosp, Matrahaza, Hungary
[3] TESARO Inc, Waltham, MA USA
[4] Tufts Med Ctr, Boston, MA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.9636
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9636
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of rolapitant in the prevention of chemotherapy-induced nausea and vomiting (CINV) in elderly patients
    Aapro, M. S.
    Arora, S.
    Powers, D.
    ANNALS OF ONCOLOGY, 2016, 27
  • [22] ROLAPITANT FOR THE PREVENTION OF NAUSEA IN PATIENTS RECEIVING MODERATELY OR HIGHLY EMETOGENIC CHEMOTHERAPY.
    Nagy, Cindy
    Clark-Snow, Rebecca
    Arora, Sujata
    Powers, Dan
    Navari, Rudolph
    ONCOLOGY NURSING FORUM, 2016, 43 (02) : 127 - 127
  • [23] Rolapitant for the prevention of nausea in patients receiving moderately or highly emetogenic chemotherapy.
    Navari, Rudolph M.
    Nagy, Cindy K.
    Arora, Sujata
    Powers, Daniel
    Clark-Snow, Rebecca Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (26)
  • [24] Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
    Gao, Ai
    Guan, Shasha
    Sun, Yinjuan
    Wang, Lingling
    Meng, Fanlu
    Liu, Xia
    Gu, Liyan
    Li, Guo
    Zhong, Diansheng
    Zhang, Linlin
    BMC CANCER, 2023, 23 (01)
  • [25] Prolonged usage of fosaprepitant for prevention of delayed chemotherapy-induced nausea and vomiting(CINV) in patients receiving highly emetogenic chemotherapy
    Ai Gao
    Shasha Guan
    Yinjuan Sun
    Lingling Wang
    Fanlu Meng
    Xia Liu
    Liyan Gu
    Guo Li
    Diansheng Zhong
    Linlin Zhang
    BMC Cancer, 23
  • [26] Phase III results for the novel neurokinin-1 (NK-1) receptor antagonist, casopitant: 3-day IV/oral dosing regimen for chemotherapy-induced nausea and vomiting (CINV) in patients (Pts) receiving moderately emetogenic chemotherapy (MEC)
    Aziz, Z.
    Arpornwirat, W.
    Herrstedt, J.
    Camlett, I.
    Piontek, T.
    Ranganathan, S.
    Schnyder, J.
    Bandekar, R. R.
    Levin, J.
    Shaharyar, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [27] Rolapitant for the prevention of chemotherapy-induced nausea and vomiting in breast cancer patients receiving multiple cycles of emetogenic chemotherapy
    Schwartzberg, L.
    Navari, R.
    Arora, S.
    Powers, D.
    Jordan, K.
    Rapoport, B.
    CANCER RESEARCH, 2017, 77
  • [28] Impact of rolapitant on quality of life (QoL) in patients (pts) receiving highly emetogenic chemotherapy (HEC) and moderately emetogenic chemotherapy (MEC)
    Chasen, Martin
    Urban, Laszlo
    Schnadig, Ian
    Rapoport, Bernardo Leon
    Poma, Allen
    Arora, Sujata
    Navari, Rudolph M.
    Schwartzberg, Lee Steven
    Gridelli, Cesare
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [29] Rolapitant for Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) in Patients With Breast Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2016, 14 (08) : 6 - 7
  • [30] Incidence of chemotherapy-induced nausea and vomiting (CINV) after highly and moderately emetogenic therapy in the era of NK-1 inhibitors - perception versus reality
    Perez-Altozano, J.
    Majem, M.
    Calvo, N.
    Moreno, E.
    Feliu, A.
    Gich, I.
    Mangues, A.
    Barnadas, A.
    EJC SUPPLEMENTS, 2009, 7 (02): : 184 - 184
12345